Improving efficiency of inferences in randomized clinical trials using auxiliary covariates.
about
Connections between survey calibration estimators and semiparametric models for incomplete data.Multiple imputation methods for handling missing data in cost-effectiveness analyses that use data from hierarchical studies: an application to cluster randomized trials.Use of auxiliary covariates in estimating a biomarker-adjusted treatment effect model with clinical trial data.Nonparametric estimation for censored mixture data with application to the Cooperative Huntington's Observational Research Trial.Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data.Evaluating surrogate marker information using censored data.Optimal auxiliary-covariate-based two-phase sampling design for semiparametric efficient estimation of a mean or mean difference, with application to clinical trialsAnalysis of randomized comparative clinical trial data for personalized treatment selectionsDapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebo-controlled trial.On the covariate-adjusted estimation for an overall treatment difference with data from a randomized comparative clinical trialIncreasing the Efficiency of Prevention Trials by Incorporating Baseline CovariatesStatistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials.Semiparametric inference for a 2-stage outcome-auxiliary-dependent sampling design with continuous outcome.A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy.On optimal treatment regimes selection for mean survival time.Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial.Semiparametric estimation of treatment effect with time-lagged response in the presence of informative censoring.Variable selection for optimal treatment decision.Adaptive pre-specification in randomized trials with and without pair-matching.Augmented generalized estimating equations for improving efficiency and validity of estimation in cluster randomized trials by leveraging cluster-level and individual-level covariates.A Sequential Phase 2b Trial Design for Evaluating Vaccine Efficacy and Immune Correlates for Multiple HIV Vaccine RegimensEvidence for age-associated cognitive decline from Internet game scoresEfficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: Results of the interim analysis of 16-week double-blind treatment periodEfficient and robust method for comparing the immunogenicity of candidate vaccines in randomized clinical trialsLeveraging prognostic baseline variables to gain precision in randomized trialsAccounting for interactions and complex inter-subject dependency in estimating treatment effect in cluster-randomized trials with missing outcomes.Using regression models to analyze randomized trials: asymptotically valid hypothesis tests despite incorrectly specified models.Variable selection for covariate-adjusted semiparametric inference in randomized clinical trials.Feasibility of a computerized intervention for offenders with substance use disorders: a research note.Identifying predictive markers for personalized treatment selection.Doubly robust inference for targeted minimum loss-based estimation in randomized trials with missing outcome data.On adjustment for auxiliary covariates in additive hazard models for the analysis of randomized experiments.Improve efficiency and reduce bias of Cox regression models for two-stage randomization designs using auxiliary covariates.Boosting the precision of mediation analyses of randomised experiments through covariate adjustment.Dapagliflozin in the treatment of patients with type 2 diabetes presenting with high baseline A1C.Landmark estimation of survival and treatment effects in observational studies.Covariate adjustment in randomized trials with binary outcomes: targeted maximum likelihood estimation.One-year efficacy and safety of saxagliptin add-on in patients receiving dapagliflozin and metformin.Efficacy and safety of triple therapy with dapagliflozin add-on to saxagliptin plus metformin over 52 weeks in patients with type 2 diabetes.Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: A randomized controlled trial.
P2860
Q30653939-09064687-1329-48A1-929A-30FA46952DC3Q30659221-7801EBD6-2126-4768-BE2E-C622728EA8CFQ30717235-3070C6D6-F284-4FCA-A468-46C3EB1D95F0Q30747024-0730EF03-75E3-42C5-9403-E3A6B82ADF67Q30903369-C7D9F61D-EBEC-49A1-9E22-E02C478E180EQ31154746-376847CA-420E-45C4-9E61-433B09690382Q33611244-11FF99F6-9FA5-4838-B2BE-57597AFBFB64Q33704826-63648B8A-2FE0-4626-A314-21CABD22E631Q33785136-AC50F588-F829-43D4-B3F8-AEDF9C0DA68EQ34147369-22D7E6DD-373F-4FF1-9C63-81990D654057Q34383812-C87A48ED-600A-41C2-A622-ADF8C35D43CBQ34743329-2ABE257A-C508-4A9E-A496-74AF0B3A5BF7Q35044256-A3A83A3E-CD44-482E-9B57-164580EC3CB7Q35102138-2250A1E6-2E4E-46A2-AFA9-3B867CBA8DFFQ35164135-A8144196-C7E9-4C38-B574-CFD9C9B56241Q35179843-1D322259-D179-4BB2-9DE6-DBC2118D275DQ35553170-19EBAF2E-C0F7-48F4-9003-CBAE8755902FQ35830773-5F31C2A2-4ACC-4572-87E9-69B2B2E870E0Q36082493-407B3268-019A-482E-80E3-3E7B25C3C637Q36390470-174EB3F2-F4FD-43FC-A812-AF954098E878Q36413788-6F3BE356-FE5E-49ED-9F94-C525AF14C271Q36926758-E413D3EC-EA9E-4CDF-B36E-26ADFC78F18AQ37060860-293A3810-D326-4A24-BC46-88F9115FF394Q37122099-B0462E2D-45A9-43F8-B202-8D0F959F7C2FQ37246685-EA079E31-A152-4D39-A9F5-184D528AC8E7Q37322419-782E298A-61C3-4990-B350-1ECAEC9FCB2BQ37356269-BC783002-2DB9-499F-8AA3-FA1D9D549971Q37374617-65F1F905-6032-4615-BD68-3EDEB4E76629Q37623327-4C87A2E1-7B98-478E-AC1F-2010CE514724Q37702844-F5393CF9-CD07-4586-BB7C-17E8D84B4C0DQ38660972-7F4542FA-4940-4967-8D57-600A853862E5Q38697612-F5CD0766-B5A5-45F9-A2B6-C31B4241F2BDQ38969245-E1337435-91C0-4FC0-B8FA-B39887F84C1CQ39029893-ECFFCDC9-08C9-4F8B-8394-8C028D97BF7FQ39865389-096B3814-4E40-426A-93C7-E5FA6490BF10Q39994581-409B7FF9-1B18-4580-842A-D6D6BE2F8F28Q40121631-D1084F34-9C15-4301-9D7D-95AD7BFA5DA9Q40617003-2CEE8B7F-9BB7-4DD8-BA2A-64DA5A7B0D6CQ40623052-E10B770B-0C50-4A83-9602-95ED11A31852Q40901927-0E7C0CA6-76D3-49D2-9433-FAA47070DD7B
P2860
Improving efficiency of inferences in randomized clinical trials using auxiliary covariates.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Improving efficiency of infere ...... ls using auxiliary covariates.
@en
type
label
Improving efficiency of infere ...... ls using auxiliary covariates.
@en
prefLabel
Improving efficiency of infere ...... ls using auxiliary covariates.
@en
P2093
P2860
P1433
P1476
Improving efficiency of infere ...... ls using auxiliary covariates.
@en
P2093
Anastasios A Tsiatis
Marie Davidian
P2860
P304
P356
10.1111/J.1541-0420.2007.00976.X
P407
P577
2008-01-11T00:00:00Z